Ribociclib plus endocrine therapy offers survival benefit for postmenopausal patients with metastatic breast cancer

A study led by researchers from The University of Texas MD Anderson Cancer Center showed a significant overall survival benefit with ribociclib plus endocrine therapy for postmenopausal patients with hormone receptor-positive (HR+) human epidermal growth factor receptor 2-negative…

Source: www.news-medical.net – Read more